Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

"SPRAVATO® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

The U.S. Food and Drug Administration (FDA) has broadened its approval for Johnson & Johnson's nasal spray, Spravato esketamine, allowing its use as a monotherapy for severe depression ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...

This week, the US Food and Drug Administration expanded its approval of Spravato, an antidepressant nasal spray. The drug, made by Johnson & Johnson, is now cleared for use as the only standalone ...